Acorai

Executive Summary

Acorai is a Swedish medtech company addressing the critical need for non-invasive monitoring of cardiac and pulmonary pressures in heart failure patients. Current gold-standard methods require invasive catheterization, limiting frequency and increasing risk. Acorai’s SAVE Sensor System integrates seismic, acoustic, visual, and electric sensors to non-invasively detect hemodynamic congestion, enabling personalized therapy adjustments. The platform has been clinically tested in over 2,000 patients, demonstrating feasibility and accuracy. By providing real-time, accessible pressure data, Acorai aims to reduce hospitalizations, improve outcomes, and lower healthcare costs. Founded in 2019 and based in Stockholm, the company is well-positioned in the cardiovascular digital health space, with significant potential to transform heart failure management globally.

Upcoming Catalysts (preview)

• Q4 2026Publication of pivotal clinical study results80% success
• Q2 2027CE marking approval for SAVE Sensor System60% success
• Q1 2027Partnership with major European hospital network for pilot deployment70% success